Femto Technologies Inc., a leader in the FemTech sector, has successfully completed a private placement raising approximately $17 million. The funding was achieved through the sale of Common Units and warrants, with the transaction closing on February 28, 2025. This financial move involved the issuance of 4,076,736 Common Units priced at $4.17 per unit, alongside Series A and Series B Warrants with exercise prices of $5.21 and $12.51 per share, respectively.
The proceeds from this placement are earmarked for general corporate purposes and working capital, with a significant portion allocated to the continued development of Sensera. Sensera is a groundbreaking feminine wellness device that leverages the proprietary Smart Release System (SRS) technology, which incorporates machine learning and artificial intelligence to offer a personalized self-care experience for women. The device's innovative approach recently earned it a CES Innovation Awards® 2025 Honorary mention in the AI category.
This funding round was managed exclusively by Aegis Capital Corp., with legal representation from Louis A. Brilleman, P.C. for Femto Technologies and Kaufman & Canoles, P.C. for Aegis Capital Corp. As a publicly traded entity on Nasdaq under the ticker FMTO, Femto Technologies is at the forefront of integrating advanced technology into women's wellness, setting new standards in the FemTech industry.
The implications of this funding are vast, not only for Femto Technologies but for the FemTech industry at large. It underscores the growing recognition of the importance of technology-driven solutions in addressing women's health and wellness needs. The development of Sensera, with its AI and machine learning capabilities, represents a significant leap forward in personalized healthcare, offering potential benefits that extend beyond individual wellness to impact broader societal health outcomes.
